2022 - Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform

Chinese hamster ovary (CHO) cells have been the cell line of choice for producing most biotherapeutics. The dihydrofolate reductase (DHFR)-deficient CHO DG44 is a well characterized cell line that exhibits long-term stability and is a universally accepted platform in the industry for producing diverse monoclonal antibodies and proteins. However, there are different challenges faced by the biopharmaceutical industry while using the CHO DG44 platform, including prolonged timelines from gene synthesis to production of a research cell bank and the low product titers. Improved process design as well as vector modifications can help address both limitations to improve titers and to achieve faster results for expediting therapeutic objectives.
In the upcoming webinar, the featured speaker will lead a discussion on the development of new generation vectors and effective process improvements to increase the utility of CHO DG44 as a cell line development platform.
Register to learn about driving better titers and shorter timelines with a robust and scalable CHO DG44 platform.